The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Comparison of the clinical benefit of an adjuvant therapy in gastrointestinal stromal tumors (GIST) with other adjuvant cancer therapies.
Morgan Deflin
Consultant or Advisory Role - Novartis
Anju Parthan
Consultant or Advisory Role - Novartis
Douglas Taylor
Consultant or Advisory Role - Novartis
John Coombs
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Medha Sasane
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Marc Paolantonio
Employment or Leadership Position - Novartis
Stock Ownership - Novartis